Summary of Panel Discussions

Introduction During the Workshop "Pharmacokinetics: Defining the Dose for Risk Assessment," two panel discussions were held. The first was "Design of Studies to Obtain Pharmacokinetic Data for Risk Assessment." Emil Pfitzer of HoffmannLa Roche, Inc.; James Stevens of Ciba-Geigy Corporation;Penelope FennerCrisp of the U.S. Environmental Protection Agency Pesticides Program; and Daniel Menzel of the University of California, Irvine, were lead discussants. The second was "How Pharmacokinetics Affects Risk Assessments in Sensitive Populations, Especially the Very Young and the Elderly" with Daniel Krewski of the Health and Welfare Canada, John Doull of the University of Kansas, Alan Wilson of Monsanto Company, and Donald Mattison of the University of Pittsburgh as lead discussants. The discussions centered around the following four questions: a) What pharmacokinetic data are needed for risk assessment? b) When should pharmacokinetic data be obtained in toxicity testing? c) How can pharmacokinetic data be applied in risk assessment? d) How is pharmacokinetics altered in sensitive populations?